OVIEDO, SPAIN — June 7, 2002 —
Shire Pharmaceuticals Group plc announces that Fosrenol (lanthanum carbonate), its new phosphate binder for use in dialysis patients, has been shown not to cause adverse effects on renal bone disease over 12 months of therapy, according to the most comprehensive controlled bone biopsy study ever undertaken in this field.
The new data is in a poster, presented for the first time at the international symposium “Advances in Renal Osteodystrophy” in Oviedo, Spain (6-7 June 2002) by the principal investigator and leading bone disease specialist Professor Marc De Broe, of the University of Antwerp’s Department of Nephrology.
Poor control of blood calcium or phosphate levels in chronic renal failure patients can result in bone disease and secondary hyperparathyroidism. Currently available medications such as calcium or aluminium-based phosphate binders can be associated with new or worsening bone disease.
These concerns make it important to monitor carefully the effects of new phosphate binders on bone metabolism. Such a comprehensive investigation into the impact of these treatments has not previously been undertaken and it is very encouraging to see that Fosrenol is well tolerated and may offer important advantages over other phosphate binders based on the results of this study.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!